B cell depletion in autoimmune disease

The CD20 cell marker appears early in the process of B cell development. In this review we focus on the results of attempts to utilize B cell depletion based on the use of a chimeric monoclonal antibody (MAb) specific for human CD20, rituximab, for the treatment of patients with autoimmune diseases....

Descripción completa

Detalles Bibliográficos
Autores principales: Gorman, Claire, Leandro, Maria, Isenberg, David
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833439/
https://www.ncbi.nlm.nih.gov/pubmed/15180893
http://dx.doi.org/10.1186/ar1007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833439/
https://www.ncbi.nlm.nih.gov/pubmed/15180893
http://dx.doi.org/10.1186/ar1007

Ejemplares similares